1,4-Benzodioxanes as reversible and irreversible antagonists at adrenergic receptors.
D000317:Adrenergic alpha-Antagonists / Q000138:chemical synthesis* / Q000494:pharmacology; D000319:Adrenergic beta-Antagonists / Q000138:chemical synthesis / Q000494:pharmacology; D000818:Animals; D001665:Binding Sites; D002118:Calcium / Q000494:pharmacology; D002217:Carbachol / Q000494:pharmacology; D004048:Diethylamines / Q000138:chemical synthesis / Q000494:pharmacology; D004147:Dioxins / Q000138:chemical synthesis* / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D006168:Guinea Pigs; D066298:In Vitro Techniques; D008297:Male; D009119:Muscle Contraction / Q000187:drug effects; D009638:Norepinephrine / Q000494:pharmacology; D010276:Parasympatholytics / Q000138:chemical synthesis / Q000494:pharmacology; D051381:Rats; D011941:Receptors, Adrenergic / Q000187:drug effects*; D014132:Trachea / Q000187:drug effects; D014649:Vas Deferens / Q000187:drug effects
D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D004048:Diethylamines; D004147:Dioxins; D010276:Parasympatholytics; D011941:Receptors, Adrenergic; D002217:Carbachol; D002118:Calcium; D009638:Norepinephrine